UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 639

Sortiert nach

The evolving role of disproportionality analysis in pharmacovigilance

Expert opinion on drug safety, 2024-08, Vol.23 (8), p.981-994

2024

Link zum Volltext

Verfügbarkeit prüfen

Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals

Drug safety, 2024-07

2024

Link zum Volltext

Verfügbarkeit prüfen

Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis

Drug safety, 2024-07, Vol.47 (7), p.601-605

2024

Link zum Volltext

Verfügbarkeit prüfen

The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement

Drug safety, 2024-06, Vol.47 (6), p.575-584

2024

Link zum Volltext

Verfügbarkeit prüfen

The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration

Drug safety, 2024-06, Vol.47 (6), p.585-599

2024

Link zum Volltext

Verfügbarkeit prüfen

Fingerprick volumetric absorptive microsampling for therapeutic drug monitoring of antiseizure medications: Reliability and real-life feasibility in epilepsy patients

Journal of pharmaceutical and biomedical analysis, 2024-05, Vol.242, p.116065-116065, Article 116065

2024

Link zum Volltext

Verfügbarkeit prüfen

Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database

Drug safety, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

Symmetrical cutaneous rash in two women

Clinical case reports, 2024-05, Vol.12 (5), p.e8877-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Symmetrical cutaneous rash in two women

Clinical case reports, 2024, Vol.12 (5), p.e8877-e8877

2024

Link zum Volltext

Verfügbarkeit prüfen

Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System

Targeted oncology, 2024-05, Vol.19 (3), p.435-445

2024

Link zum Volltext

Verfügbarkeit prüfen

Learning of clinical pharmacology by future prescribers in Bologna: Teachers' and students' reflections on the way forward

British journal of clinical pharmacology, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Enhancing Transparency in Defining Studied Drugs: The Open‑Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS

Drug safety, 2024-03, Vol.47 (3), p.271-284

2024

Link zum Volltext

Verfügbarkeit prüfen

Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS

Drug safety, 2024-03, Vol.47 (3), p.271-284

2024

Link zum Volltext

Verfügbarkeit prüfen

Fibroblasts and Endothelial Cells in Three-Dimensional Models: A New Tool for Addressing the Pathogenesis of Systemic Sclerosis as a Prototype of Fibrotic Vasculopathies

International journal of molecular sciences, 2024-02, Vol.25 (5), p.2780

2024

Link zum Volltext

Verfügbarkeit prüfen

Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?

Rheumatology (Oxford, England), 2024-02, Vol.63 (SI), p.SI4-SI13

2024

Link zum Volltext

Verfügbarkeit prüfen

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

Frontiers in Drug Safety and Regulation, 2024-01, Vol.3

2024

Link zum Volltext

Verfügbarkeit prüfen

Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database

Frontiers in pharmacology, 2024, Vol.15, p.1275814-1275814

2024

Link zum Volltext

Verfügbarkeit prüfen

The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Spontaneously Reported Adverse Events in Pharmacovigilance (READUS-PV)

Drug safety, 2023-11, Vol.46 (11), p.1264-1265

2023

Link zum Volltext

Verfügbarkeit prüfen

Suspected adverse reactions to medications and food supplements containing Serenoa repens: A worldwide analysis of pharmacovigilance and phytovigilance spontaneous reports

Phytotherapy research, 2023-11, Vol.37 (11), p.5289-5299

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the Robustness of Disproportionality Analyses from National and International Spontaneous Reporting Databases

Drug safety, 2023-11, Vol.46 (11), p.1260-1260

2023

Link zum Volltext

Verfügbarkeit prüfen

Interpretation of Pharmacovigilance Disproportionality Analyses

Clinical pharmacology and therapeutics, 2023-10, Vol.114 (4), p.745-746

2023

Link zum Volltext

Verfügbarkeit prüfen

Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events

Pharmacology & therapeutics (Oxford), 2023-10, Vol.250, p.108507-108507, Article 108507

2023

Link zum Volltext

Verfügbarkeit prüfen

Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System

Clinical drug investigation, 2023-10, Vol.43 (10), p.773-783

2023

Link zum Volltext

Verfügbarkeit prüfen

Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue

Journal of thoracic oncology, 2023-10, Vol.18 (10), p.e112-e113

2023

Link zum Volltext

Verfügbarkeit prüfen

Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach

Drug safety, 2023-10, Vol.46 (10), p.921-926

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 639

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(543)
Mit Volltextzugriff
(567)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(362)
Life Sciences & Biomedicine
(339)
Humans
(180)
Pharmacology & Pharmacy
(95)
Biological And Medical Sciences
(80)
Pharmacovigilance
(66)
Animals
(61)
Female
(59)
Male
(53)
Medicine
(52)
Medicine & Public Health
(50)
Fundamental And Applied Biological Sciences. Psychology
(48)
Carbon Dioxide
(37)
Toxicology
(37)
Pharmacology/toxicology
(36)
Plant Sciences
(36)
Medical Sciences
(35)
Drugs
(33)
Environmental Sciences & Ecology
(33)
Adult
(32)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

The evolving role of disproportionality analysis in pharmacovigilance

Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals

Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis

The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement

The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration

Fingerprick volumetric absorptive microsampling for therapeutic drug monitoring of antiseizure medications: Reliability and real-life feasibility in epilepsy patients

Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database

Symmetrical cutaneous rash in two women

Symmetrical cutaneous rash in two women

Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System

Learning of clinical pharmacology by future prescribers in Bologna: Teachers' and students' reflections on the way forward

Enhancing Transparency in Defining Studied Drugs: The Open‑Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS

Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS

Fibroblasts and Endothelial Cells in Three-Dimensional Models: A New Tool for Addressing the Pathogenesis of Systemic Sclerosis as a Prototype of Fibrotic Vasculopathies

Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database

The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Spontaneously Reported Adverse Events in Pharmacovigilance (READUS-PV)

Suspected adverse reactions to medications and food supplements containing Serenoa repens: A worldwide analysis of pharmacovigilance and phytovigilance spontaneous reports

Evaluation of the Robustness of Disproportionality Analyses from National and International Spontaneous Reporting Databases

Interpretation of Pharmacovigilance Disproportionality Analyses

Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events

Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System

Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue

Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach

Suchergebnisse filtern